These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

Benzinga07-16 20:17

Elevance Health Inc. (NYSE:ELV) on Wednesday reported upbeat second-quarter results and raised its full-year guidance.

Adjusted earnings came in at $7.45 per share, beating the analyst consensus estimate of $6.21. Revenue rose to $49.83 billion, above the consensus estimate of $48.69 billion.

Elevance now expects fiscal 2026 adjusted earnings of at least $27 per share, up from prior guidance of at least $26.75 and above the Wall Street consensus estimate of $26.91. The company also raised its fiscal 2026 operating cash flow forecast to at least $6 billion.

Elevance Health shares rose 1.8% to $397.20 in pre-market trading.

These analysts made changes to their price targets on Elevance Health following earnings announcement.

Baird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $331 to $393.
Barclays analyst Andrew Mok maintained Elevance Health with an Overweight rating and lowered the price target from $480 to $457.
Guggenheim analyst Jason Cassorla maintained the stock with a Buy and raised the price target from $399 to $455.

Considering buying ELV stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651441767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651441767","market":"hk","top_or_hot":-1,"title":"These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/ELV\">Elevance Health</a> Inc.</strong> (NYSE:ELV) on Wednesday reported upbeat second-quarter results and raised its full-year guidance.</p>\n<p>Adjusted earnings came in at $7.45 per share, beating the analyst consensus estimate of $6.21. Revenue rose to $49.83 billion, above the consensus estimate of $48.69 billion.</p>\n<p>Elevance now expects fiscal 2026 adjusted earnings of at least $27 per share, up from prior guidance of at least $26.75 and above the Wall Street consensus estimate of $26.91. The company also raised its fiscal 2026 operating cash flow forecast to at least $6 billion.</p>\n<p>Elevance Health shares rose 1.8% to $397.20 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Elevance Health following earnings announcement.</p>\n<ul>\n<li>Baird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $331 to $393.</li>\n<li>Barclays analyst Andrew Mok maintained Elevance Health with an Overweight rating and lowered the price target from $480 to $457.</li>\n<li>Guggenheim analyst Jason Cassorla maintained the stock with a Buy and raised the price target from $399 to $455.</li>\n</ul>\n<p><strong>Considering buying ELV stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"442\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/16081632/image-434-1024x442.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/16081632/image-434-1024x442.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/16081632/image-434-300x130.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/16081632/image-434-768x332.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/16081632/image-434.png 1232w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-07-16 20:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/ELV\">Elevance Health</a> Inc.</strong> (NYSE:ELV) on Wednesday reported upbeat second-quarter results and raised its full-year guidance.</p>\n<p>Adjusted earnings came in at $7.45 per share, beating the analyst consensus estimate of $6.21. Revenue rose to $49.83 billion, above the consensus estimate of $48.69 billion.</p>\n<p>Elevance now expects fiscal 2026 adjusted earnings of at least $27 per share, up from prior guidance of at least $26.75 and above the Wall Street consensus estimate of $26.91. The company also raised its fiscal 2026 operating cash flow forecast to at least $6 billion.</p>\n<p>Elevance Health shares rose 1.8% to $397.20 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Elevance Health following earnings announcement.</p>\n<ul>\n<li>Baird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $331 to $393.</li>\n<li>Barclays analyst Andrew Mok maintained Elevance Health with an Overweight rating and lowered the price target from $480 to $457.</li>\n<li>Guggenheim analyst Jason Cassorla maintained the stock with a Buy and raised the price target from $399 to $455.</li>\n</ul>\n<p><strong>Considering buying ELV stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"442\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/16081632/image-434-1024x442.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/16081632/image-434-1024x442.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/16081632/image-434-300x130.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/16081632/image-434-768x332.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/16081632/image-434.png 1232w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELV","symbol_name":"Elevance Health","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/07/60493503/these-analysts-revise-their-forecasts-on-elevance-health-following-q2-earnings","article_id":"2651441767","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651441767","pubTimestamp":1784204266,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Elevance Health Inc. (NYSE:ELV) reported strong Q2 results and raised full-year guidance. Analysts have adjusted price targets for ELV stock.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ELV":"Elevance Health"},"translate_title":"这些分析师在第二季度收益公布后修改了对 Elevance Health 的预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELV":1.5},"content_text":"Elevance Health Inc. (NYSE:ELV) on Wednesday reported upbeat second-quarter results and raised its full-year guidance.\nAdjusted earnings came in at $7.45 per share, beating the analyst consensus estimate of $6.21. Revenue rose to $49.83 billion, above the consensus estimate of $48.69 billion.\nElevance now expects fiscal 2026 adjusted earnings of at least $27 per share, up from prior guidance of at least $26.75 and above the Wall Street consensus estimate of $26.91. The company also raised its fiscal 2026 operating cash flow forecast to at least $6 billion.\nElevance Health shares rose 1.8% to $397.20 in pre-market trading.\nThese analysts made changes to their price targets on Elevance Health following earnings announcement.\n\nBaird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $331 to $393.\nBarclays analyst Andrew Mok maintained Elevance Health with an Overweight rating and lowered the price target from $480 to $457.\nGuggenheim analyst Jason Cassorla maintained the stock with a Buy and raised the price target from $399 to $455.\n\nConsidering buying ELV stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651441767","isCrawlerRequest":true}